Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan
Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan have?
Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan has 17 citations in the OpenAlex counts ScholarIQ stores.
When was Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan published?
Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan has 2021 year in the ScholarIQ index.
What is the open-access status of Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan?
Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan has closed oa status in the ScholarIQ index.
What is the DOI of Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan?
The DOI for Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan is on the source record.
What is the PMID of Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan?
The PMID for Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan is on the source record.
What is the OpenAlex record for Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan?
The OpenAlex for Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan is on the source record.